Qureing antibiotic resistance

QureTech Bio AB is targeting chlamydia and tuberculosis with compounds that disable, rather than kill, pathogens to circumvent antibiotic resistance. By targeting the organisms' virulence factors, the company hopes to spare the host flora and create antibacterials that fight infections while preserving the microbiome.

The company is raising funds for lead optimization in 2016 with the goal of filing an IND by the end of 2018...